Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6952808 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL26157632 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL6953888 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL25865981 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL14389110 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL20977729 | 1.00 | MEN1 (0.50) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL8971720 | 0.98 | MEN1 (0.48) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL21071452 | 0.95 | MEN1 (0.47) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL22609514 | 0.95 | MEN1 (0.47) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 | |
| SCHEMBL6575753 | 0.94 | MEN1 (0.48) | MEN1KMT2ASIGMAR1KDM4CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144798-A1 | IONIZABLE CATIONIC LIPIDS FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023135846-A1 | FLUORINATED COMPOUND AND CONTRAST MEDIUM | TDK株式会社 | 2023-07-20 | — | — | WO | disclosed |
| US-6646129-B2 | Treatment of psoriasis and skin cancer | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984936-B1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S | 2002-08-08 | — | — | US | disclosed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
| EP-0984936-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054141-A1 | CYANOGUANIDINES AS CELL PROLIFERATION INHIBITORS | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107400-A1 | Cyanoguanidines as cell proliferation inhibitors | CCNC, MKI67, CCNI | MEN1 1494/4885KMT2A 2909/4885SIGMAR1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.